Bionized Nanoferrite Particles Alter the Course of Experimental Cryptococcus Neoformans Pneumonia

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2022 Mar 16

PMID 35293784

Authors

Livia C Liporagi Lopes

Preethi Korangath

Samuel R Dos Santos Jr

Kathleen L Gabrielson

Robert Ivkov

Arturo Casadevall

Affiliations

Soon will be listed here.

Abstract

Cryptococcosis is a devastating fungal disease associated with high morbidity and mortality even when treated with antifungal drugs. Bionized nanoferrite (BNF) nanoparticles are powerful immunomodulators, but their efficacy for infectious diseases has not been investigated. Administration of BNF nanoparticles to mice with experimental cryptococcal pneumonia altered the outcome of infection in a dose response manner as measured by CFU and survival. The protective effects were higher at lower doses, with reductions in IL-2, IL-4, and TNF-α, consistent with immune modulation whereby reductions in inflammation translate into reduced host damage, clearance of infection, and longer survival.

References

Gonzalez-Aramundiz J, Cordeiro A, Csaba N, Fuente M, Alonso M . Nanovaccines : nanocarriers for antigen delivery. Biol Aujourdhui. 2013; 206(4):249-61. DOI: 10.1051/jbio/2012027. View

Panackal A, Williamson K, van de Beek D, Boulware D, Williamson P . Fighting the Monster: Applying the Host Damage Framework to Human Central Nervous System Infections. mBio. 2016; 7(1):e01906-15. PMC: 4742705. DOI: 10.1128/mBio.01906-15. View

Goldman D, Khine H, Abadi J, Lindenberg D, Pirofski La , Niang R . Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics. 2001; 107(5):E66. DOI: 10.1542/peds.107.5.e66. View

Ghannoum M, Rice L . Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999; 12(4):501-17. PMC: 88922. DOI: 10.1128/CMR.12.4.501. View

Korangath P, Barnett J, Sharma A, Henderson E, Stewart J, Yu S . Nanoparticle interactions with immune cells dominate tumor retention and induce T cell-mediated tumor suppression in models of breast cancer. Sci Adv. 2020; 6(13):eaay1601. PMC: 7096167. DOI: 10.1126/sciadv.aay1601. View

Gobbo O, Sjaastad K, Radomski M, Volkov Y, Prina-Mello A . Magnetic Nanoparticles in Cancer Theranostics. Theranostics. 2015; 5(11):1249-63. PMC: 4568452. DOI: 10.7150/thno.11544. View

Kwon-Chung K, Fraser J, Doering T, Wang Z, Janbon G, Idnurm A . Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med. 2014; 4(7):a019760. PMC: 4066639. DOI: 10.1101/cshperspect.a019760. View

Franzot S, Mukherjee J, CHERNIAK R, Chen L, Hamdan J, Casadevall A . Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun. 1998; 66(1):89-97. PMC: 107863. DOI: 10.1128/IAI.66.1.89-97.1998. View

Deng Z, Jin J, Wang Z, Wang Y, Gao Q, Zhao J . The metal nanoparticle-induced inflammatory response is regulated by SIRT1 through NF-κB deacetylation in aseptic loosening. Int J Nanomedicine. 2017; 12:3617-3636. PMC: 5439723. DOI: 10.2147/IJN.S124661. View

10.

Mallipeddi R, Rohan L . Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomedicine. 2010; 5:533-47. PMC: 2950411. View

11.

Mocan T, Matea C, Iancu C, Agoston-Coldea L, Mocan L, Orasan R . Hypersensitivity and nanoparticles: update and research trends. Clujul Med. 2016; 89(2):216-9. PMC: 4849378. DOI: 10.15386/cjmed-574. View

12.

Arias L, Pessan J, Vieira A, Lima T, Delbem A, Monteiro D . Iron Oxide Nanoparticles for Biomedical Applications: A Perspective on Synthesis, Drugs, Antimicrobial Activity, and Toxicity. Antibiotics (Basel). 2018; 7(2). PMC: 6023022. DOI: 10.3390/antibiotics7020046. View

13.

Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson K . Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A. 2008; 105(38):14265-70. PMC: 2567179. DOI: 10.1073/pnas.0805135105. View

14.

Blanco E, Shen H, Ferrari M . Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015; 33(9):941-51. PMC: 4978509. DOI: 10.1038/nbt.3330. View

15.

Coelho C, Bocca A, Casadevall A . The intracellular life of Cryptococcus neoformans. Annu Rev Pathol. 2013; 9:219-38. PMC: 5127716. DOI: 10.1146/annurev-pathol-012513-104653. View

16.

Franca A, Aggarwal P, Barsov E, Kozlov S, Dobrovolskaia M, Gonzalez-Fernandez A . Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro. Nanomedicine (Lond). 2011; 6(7):1175-88. PMC: 3912350. DOI: 10.2217/nnm.11.41. View

17.

Kim C, Nguyen H, Ignacio R, Kim J, Cho H, Maeng E . Immunotoxicity of zinc oxide nanoparticles with different size and electrostatic charge. Int J Nanomedicine. 2015; 9 Suppl 2:195-205. PMC: 4279726. DOI: 10.2147/IJN.S57935. View

18.

Casadevall A, Cleare W, Feldmesser M, Glatman-Freedman A, Goldman D, Kozel T . Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother. 1998; 42(6):1437-46. PMC: 105619. DOI: 10.1128/AAC.42.6.1437. View

19.

Ngobili T, Daniele M . Nanoparticles and direct immunosuppression. Exp Biol Med (Maywood). 2016; 241(10):1064-73. PMC: 4950368. DOI: 10.1177/1535370216650053. View

20.

Coelho C, Camacho E, Salas A, Alanio A, Casadevall A . Intranasal Inoculation of Cryptococcus neoformans in Mice Produces Nasal Infection with Rapid Brain Dissemination. mSphere. 2019; 4(4). PMC: 6686232. DOI: 10.1128/mSphere.00483-19. View